About
Science
Investors
Contact us
About
About BerGenBio
Management Team
Board of Directors
Scientific Advisory Board
Partners
Science
Pipeline
BEMCENTINIB | NSCLC
BEMCENTINIB | SRI
BEMCENTINIB | AML
Publications
Investors
Share Information and Policies
Share Data
Largest Shareholders
Stock Exchange Notices
Analyst Coverage
News
Financial Reports
Presentations
Financial Calendar
Corporate Governance
General Meetings
Environmental social and governance - ESG
Investor Relations
Contact us
Merger between BerGenBio ASA and Oncoinvent ASA
M
e
r
g
e
r
b
e
t
w
e
e
n
B
e
r
G
e
n
B
i
o
A
S
A
a
n
d
O
n
c
o
i
n
v
e
n
t
A
S
A
EGM 4 August 2025
Webcasts 2 July 2025
Learn About Us
Read more
Latest news
Read more
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
Recent News
24th October 2025
BerGenBio and Oncoinvent – Key Dates for Completion of Merger
Read more
17th September 2025
BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue
Read more
17th September 2025
BerGenBio ASA: Updated information regarding the contemplated Rights Issue and Merger
Read more
20th August 2025
BerGenBio First half results 2025
Read more
5th August 2025
BerGenBio ASA – Updated key information related to the rights issue
Read more
4th August 2025
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue
Read more
3rd July 2025
BerGenBio ASA: Notice of Extraordinary General Meeting
Read more
30th June 2025
BerGenBio ASA – Key information related to the rights issue
Read more
30th June 2025
Announcement of fully underwritten rights issue
Read more
All news
